A major therapeutic barrier in melanoma is the coexistence of diverse cellular states marked by distinct metabolic traits. Transitioning from a proliferative to an invasive melanoma phenotype is coupled with increased ferroptosis vulnerability. However, the regulatory circuits controlling ferroptosis susceptibility across melanoma cell states are unknown. In this work, we identified Apolipoprotein E (
APOE
) as the top lipid-metabolism gene segregating the melanoma MITF
high
/AXL
low
proliferative/ferroptosis-resistant from MITF
low
/AXL
high
invasive/ferroptosis-sensitive state. Mechanistically, ApoE secreted by the MITF
high
/AXL
low
cells protects the invasive phenotype from ferroptosis-inducing agents by reducing the content of peroxidation-prone polyunsaturated fatty acids and boosting GPX4 levels both in vitro and in vivo. Whole-exome sequencing indicates that
APOE
high
expression in patients with melanoma is associated with resistance to ferroptosis, regardless of
APOE
germline status. In aggregate, we found a ferroptosis-resistance mechanism between melanoma cell states relying on secreted ApoE and
APOE
high
expression as a potential biomarker for poor ferroptosis response in melanoma.